Prevencio Selected for Prestigious MedTech Innovator 2024 Accelerator Cohort
KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc., a leader in AI-powered blood tests for cardiovascular diagnostics, has been selected to join the 2024 Accelerator Cohort of MedTech Innovator, the world’s largest accelerator for medical technology companies. This honor places Prevencio among the top 5% of 1,300 applicants, reflecting the company’s innovative approach to improving cardiac health.
Prevencio’s selection follows a competitive process, with the cohort including 65 companies poised to gain significant exposure to a leading global ecosystem of healthcare experts, investors, strategic manufacturers, and other industry stakeholders. This platform will aid Prevencio in accelerating its mission to revolutionize cardiovascular diagnostics.
“We are honored and grateful to be recognized in MedTech Innovator’s 2024 Cohort. This is an incredible opportunity for Prevencio to accelerate our mission of revolutionizing the cardiovascular diagnostic sector with our innovative AI-powered HART blood tests that are accurate, actionable, and accessible”, stated Rhonda Rhyne, Prevencio’s CEO. “Our inclusion is a testament to the hard work and dedication of our entire team. We are excited to embark on this journey and make significant strides in advancing our technology to improve cardiac healthcare.”
Since MedTech Innovator’s launch, more than 600 graduate companies have achieved 310 FDA approvals and clearances, 45 exits and acquisitions, and secured $8 billion in follow-on funding. The program is renowned for identifying and refining the most innovative medtech startups worldwide.
“Having evaluated thousands of applicant companies, the 2024 MedTech Innovator Cohort represents the best emerging startups around the globe,” said Paul Grand, CEO and founder of MedTech Innovator. “We are excited to spend time with our industry-leading corporate partners and subject matter experts to guide Prevencio to advance their AI-based cardiac diagnostics to improve the lives of millions of patients.”
Prevencio’s inclusion in the accelerator program will culminate in a competition for $800,000 in non-dilutive funding.
About Prevencio HART Tests: Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics for diagnostic, medical device and pharmaceutical companies. Employing this novel approach, the company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications.
Prevencio’s two commercial tests, HART CVE and HART CADhs, are designed to provide critical insights into cardiovascular health:
- HART CVE™: Assesses one-year risk of heart attack, stroke, or cardiac death.
- HART CADhs™: Diagnosis obstructive coronary artery disease.
For additional information, visit Prevencio.
HART test results have been peer-reviewed published 34 times, including at leading cardiovascular meetings—(European Society of Cardiology Congress; American College of Cardiology Scientific Sessions; American Heart Association Scientific Sessions; American Diabetes Association Scientific Sessions; Pediatric Academic Societies International Sessions; International Spinal Cord Society Scientific Sessions; ASTRO Scientific Sessions; Transcatheter Cardiovascular Therapeutics Sessions; American Society of Clinical Oncology Genitourinary; and International Kawasaki Disease Symposium) and in top-tier journals—(Journal of American College of Cardiology; American Journal of Cardiology; Clinical Cardiology; Open Heart; Biomarkers in Medicine; Journal of American Heart Association; European Journal of Preventive Cardiology; and International Journal of Cardiology).
About Prevencio, Inc.
Prevencio’s value proposition is “Power of AI to Prevent the Preventable” — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for cardiovascular disease & beyond. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, genetic risk scores and coronary artery calcium. The company is headquartered in Kirkland, Washington. For additional information, visit Prevencio, Inc.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, and size, the accuracy of which is necessarily subject to various uncertainties of development-stage companies. The company does not undertake to update disclosures contained in this press release.
Contacts
Christiaan Boer, cboer@cplusc.com; 206-557-4309
